Compare IPCA Labs with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUN PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUN PHARMA IPCA LABS/
SUN PHARMA
 
P/E (TTM) x 23.1 27.9 82.8% View Chart
P/BV x 4.5 2.4 185.9% View Chart
Dividend Yield % 0.1 0.7 15.8%  

Financials

 IPCA LABS   SUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
SUN PHARMA
Mar-19
IPCA LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs695679 102.4%   
Low Rs400375 106.6%   
Sales per share (Unadj.) Rs260.2121.1 214.8%  
Earnings per share (Unadj.) Rs19.013.4 141.8%  
Cash flow per share (Unadj.) Rs33.120.7 159.8%  
Dividends per share (Unadj.) Rs1.002.75 36.4%  
Dividend yield (eoy) %0.20.5 35.0%  
Book value per share (Unadj.) Rs213.0172.6 123.4%  
Shares outstanding (eoy) m126.202,399.26 5.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.4 48.4%   
Avg P/E ratio x28.939.4 73.3%  
P/CF ratio (eoy) x16.625.5 65.0%  
Price / Book Value ratio x2.63.1 84.2%  
Dividend payout %5.320.6 25.6%   
Avg Mkt Cap Rs m69,1201,264,650 5.5%   
No. of employees `00013.317.5 75.7%   
Total wages/salary Rs m7,35959,671 12.3%   
Avg. sales/employee Rs Th2,477.416,608.1 14.9%   
Avg. wages/employee Rs Th555.23,409.6 16.3%   
Avg. net profit/employee Rs Th180.61,833.8 9.9%   
INCOME DATA
Net Sales Rs m32,836290,659 11.3%  
Other income Rs m41810,255 4.1%   
Total revenues Rs m33,254300,914 11.1%   
Gross profit Rs m4,50563,076 7.1%  
Depreciation Rs m1,77717,533 10.1%   
Interest Rs m2405,553 4.3%   
Profit before tax Rs m2,90550,246 5.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m5116,009 8.5%   
Profit after tax Rs m2,39432,093 7.5%  
Gross profit margin %13.721.7 63.2%  
Effective tax rate %17.612.0 147.1%   
Net profit margin %7.311.0 66.0%  
BALANCE SHEET DATA
Current assets Rs m19,455310,692 6.3%   
Current liabilities Rs m10,076173,396 5.8%   
Net working cap to sales %28.647.2 60.5%  
Current ratio x1.91.8 107.8%  
Inventory Days Days9899 98.8%  
Debtors Days Days67112 60.0%  
Net fixed assets Rs m20,260232,477 8.7%   
Share capital Rs m2522,399 10.5%   
"Free" reserves Rs m26,633411,691 6.5%   
Net worth Rs m26,886414,091 6.5%   
Long term debt Rs m2,34015,226 15.4%   
Total assets Rs m41,173646,938 6.4%  
Interest coverage x13.110.0 130.3%   
Debt to equity ratio x0.10 236.7%  
Sales to assets ratio x0.80.4 177.5%   
Return on assets %6.45.8 110.0%  
Return on equity %8.97.8 114.9%  
Return on capital %10.810.2 105.8%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64266,025 23.7%   
Fx outflow Rs m4,88438,610 12.6%   
Net fx Rs m10,75927,415 39.2%   
CASH FLOW
From Operations Rs m3,41121,965 15.5%  
From Investments Rs m-1,354-6,813 19.9%  
From Financial Activity Rs m-1,304-27,305 4.8%  
Net Cashflow Rs m753-8,442 -8.9%  

Share Holding

Indian Promoters % 45.9 63.7 72.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.1 222.2%  
FIIs % 25.3 23.0 110.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.3 209.6%  
Shareholders   36,892 133,026 27.7%  
Pledged promoter(s) holding % 2.1 0.5 403.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS